Robert E Ratner

Summary

Country: USA

Publications

  1. pmc An update on the Diabetes Prevention Program
    Robert E Ratner
    MedStar Research Institute, Hyattsville, Maryland, USA
    Endocr Pract 12:20-4. 2006
  2. ncbi Pramlintide: A new tool in diabetes management
    Laura L Want
    Curr Diab Rep 6:344-9. 2006
  3. pmc Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
    R E Ratner
    Medstar Research Institute and Georgetown University Medical School, Washington, DC, USA
    Diabet Med 27:1024-32. 2010
  4. pmc Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
    Robert Ratner
    MedStar Health Research Institute, Hyattsville, MD, USA
    Cardiovasc Diabetol 10:22. 2011
  5. doi Prevention of type 2 diabetes in women with previous gestational diabetes
    Robert E Ratner
    MedStar Research Institute, 6495 New Hampshire Ave, Hyattsville, MD 20783, USA
    Diabetes Care 30:S242-5. 2007
  6. ncbi Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes
    Robert E Ratner
    MedStar Research Institute, Hyattsville, MD 20783, USA
    Diab Vasc Dis Res 4:214-21. 2007
  7. doi Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics
    Robert E Ratner
    MedStar Research Institute, Washington, DC, USA
    Am Heart J 156:1074-9. 2008
  8. ncbi Incretin-based therapies for type 2 diabetes: clinical utility
    Robert Ratner
    MedStar Research Institute, Hyattsville, MD 20783, USA
    Endocrinol Metab Clin North Am 35:12-6; discussion 17-19. 2006
  9. doi Treatment recommendations for prediabetes
    Robert E Ratner
    MedStar Health Research Institute, 6525 Belcrest Road, Suite 700, Hyattsville, MD 20782, USA
    Med Clin North Am 95:385-95, viii-ix. 2011
  10. pmc Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096)
    R Ratner
    MedStar Health Research Institute, Hyattsville, MD, USA
    Diabetes Obes Metab 13:1142-8. 2011

Detail Information

Publications39

  1. pmc An update on the Diabetes Prevention Program
    Robert E Ratner
    MedStar Research Institute, Hyattsville, Maryland, USA
    Endocr Pract 12:20-4. 2006
    ..To summarize the results of the Diabetes Prevention Program (DPP) and describe the additional 5-year follow-up study...
  2. ncbi Pramlintide: A new tool in diabetes management
    Laura L Want
    Curr Diab Rep 6:344-9. 2006
    ..In clinical use, pramlintide reduces postprandial glycemic excursions and improves A(1c) without the weight gain and increased risk of hypoglycemia typically seen with intensification of diabetes therapy...
  3. pmc Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
    R E Ratner
    Medstar Research Institute and Georgetown University Medical School, Washington, DC, USA
    Diabet Med 27:1024-32. 2010
    ..To evaluate the dose-response relationship of lixisenatide (AVE0010), a glucagon-like peptide-1 (GLP-1) receptor agonist, in metformin-treated patients with Type 2 diabetes...
  4. pmc Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
    Robert Ratner
    MedStar Health Research Institute, Hyattsville, MD, USA
    Cardiovasc Diabetol 10:22. 2011
    ..Keywords: GLP-1 receptor agonist, diabetes, cardiovascular safety...
  5. doi Prevention of type 2 diabetes in women with previous gestational diabetes
    Robert E Ratner
    MedStar Research Institute, 6495 New Hampshire Ave, Hyattsville, MD 20783, USA
    Diabetes Care 30:S242-5. 2007
  6. ncbi Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes
    Robert E Ratner
    MedStar Research Institute, Hyattsville, MD 20783, USA
    Diab Vasc Dis Res 4:214-21. 2007
    ..The clinical development of tesaglitazar is no longer continuing; its effects on the glucose and lipid abnormalities of type 2 diabetes suggest that the concept of dual PPARalpha/gamma agonism is worthy of further investigation...
  7. doi Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics
    Robert E Ratner
    MedStar Research Institute, Washington, DC, USA
    Am Heart J 156:1074-9. 2008
    ..Rosiglitazone, a thiazolidinedione, has effects on insulin sensitivity and cardiovascular risk factors that may favorably impact the progression of coronary atherosclerosis...
  8. ncbi Incretin-based therapies for type 2 diabetes: clinical utility
    Robert Ratner
    MedStar Research Institute, Hyattsville, MD 20783, USA
    Endocrinol Metab Clin North Am 35:12-6; discussion 17-19. 2006
  9. doi Treatment recommendations for prediabetes
    Robert E Ratner
    MedStar Health Research Institute, 6525 Belcrest Road, Suite 700, Hyattsville, MD 20782, USA
    Med Clin North Am 95:385-95, viii-ix. 2011
    ..Lifestyle intervention is universally accepted as the primary intervention strategy. Secondary intervention is advocated in high-risk individuals or in the absence of a clinical response to lifestyle modification...
  10. pmc Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096)
    R Ratner
    MedStar Health Research Institute, Hyattsville, MD, USA
    Diabetes Obes Metab 13:1142-8. 2011
    ..This study examined the effect of postprandial vs. preprandial insulin glulisine on weight gain and glycaemic control in type 2 diabetes patients taking basal insulin...
  11. pmc Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions
    Robert E Ratner
    MedStar Research Institute, Hyattsville, Maryland 20783, USA
    J Clin Endocrinol Metab 93:4774-9. 2008
    ..A past history of gestational diabetes mellitus (GDM) confers a very high risk of postpartum development of diabetes, particularly type 2 diabetes...
  12. ncbi Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes
    Robert E Ratner
    MedStar Research Institute, Washington, DC, USA
    Diabetes Technol Ther 4:51-61. 2002
    ....
  13. ncbi Combination pharmacotherapy with incretins: what works best and when?
    Rebecca K Over
    MedStar Research Institute, 6495 New Hampshire Avenue, Suite 201, Hyattsville, MD 20783, USA
    Curr Diab Rep 8:361-7. 2008
    ..New incretin-based approaches offer promising new strategies for treating T2DM by recruiting new, physiologically based mechanisms of action for glucoregulation in the context of a favorable safety profile...
  14. pmc Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience
    Mihriye Mete
    MedStar Health Research Institute, Hyattsville, MD 20782, USA
    J Diabetes Complications 25:362-7. 2011
    ..This post hoc analysis from the Stop Atherosclerosis in Native Diabetics Study examines the role of baseline glycemia in achieving standard and aggressive targets and outcomes after 36 months...
  15. doi Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial
    Barbara V Howard
    MedStar Research Institute, 6495 New Hampshire Ave, Suite 201, Hyattsville, MD 20783, USA
    JAMA 299:1678-89. 2008
    ..Individuals with diabetes are at increased risk for cardiovascular disease (CVD), but more aggressive targets for risk factor control have not been tested...
  16. ncbi Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk
    Gabriel I Uwaifo
    Georgetown University College of Medicine, Washington, District of Columbia 20003, USA
    Am J Cardiol 99:51B-67B. 2007
    ..This review presents the available data on the effects of the various OHAs on cardiovascular risk surrogates and actual events in retrospective and prospective study design settings...
  17. ncbi Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey
    Helaine E Resnick
    Department of Epidemiology and Statistics, MedStar Research Institute, 6495 New Hampshire Ave, Suite 201, Hyattsville, MD 20783
    Diabetes Care 29:531-7. 2006
    ..To estimate the proportion of U.S. adults with diabetes who meet American Diabetes Association (ADA) clinical practice recommendations...
  18. ncbi The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease
    Gabriel I Uwaifo
    MedStar Research Institute, Hyattsville, Maryland 20783, USA
    Am J Med 115:12S-19S. 2003
    ..These effects remain to be substantiated by the results of large outcomes studies to evaluate the impact of glycemic control and reversal of insulin resistance on cardiovascular events...
  19. doi Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?
    Shannon D Sullivan
    Department of Endocrinology, Washington Hospital Center, 110 Irving Street, NW, Suite 2A 72, Washington, DC 20010, USA
    Curr Diab Rep 11:91-8. 2011
    ..Taken together, we recommend that prediabetic patients undergo intensive lifestyle intervention, with the addition of pharmacotherapy based on the presence of specific features of the metabolic syndrome, for diabetes prevention...
  20. ncbi Impact of computer-generated personalized goals on HbA(1c)
    Claresa S Levetan
    Department of Internal Medicine, Division of Endocrinology, Washington Hospital Center, Washington, DC, USA
    Diabetes Care 25:2-8. 2002
    ..We set forth to evaluate the impact of a system that provides uniquely formatted and personalized reports of diabetes status and goals on changes in HbA(1c) levels...
  21. pmc Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes
    Vanita R Aroda
    MedStar Health Research Institute, Hyattsville, Maryland 20782, USA
    Diabetes Technol Ther 15:117-23. 2013
    ..This study evaluated the relationship between skin intrinsic fluorescence (SIF) and long-term mean hemoglobin A1c (HbA1c) in individuals with type 1 diabetes...
  22. doi Approach to the patient with prediabetes
    Vanita R Aroda
    Med Star Clinical Research Center, 650 Pennsylvania Avenue SE, Washington, DC 20003, USA
    J Clin Endocrinol Metab 93:3259-65. 2008
    ..This article will review some of the issues surrounding the identification and treatment of prediabetes, with an interpretation of the available data to help guide management...
  23. ncbi Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors
    Barbara V Howard
    MedStar Research Institute, Washington, DC, USA
    Diabetes Care 29:391-7. 2006
    ..Diabetes has been defined as a coronary heart disease (CHD) risk equivalent, and more aggressive treatment goals have been proposed for diabetic patients...
  24. ncbi Novel pharmacologic agents for type 2 diabetes
    Gabriel I Uwaifo
    Georgetown University College of Medicine, Washington DC 20003, USA
    Endocrinol Metab Clin North Am 34:155-97. 2005
    ..There is reason to expect that despite the growing burden of diabetes worldwide, we will be better equipped to manage it and its comorbidities and prevent its onset and possibly even cure it...
  25. ncbi Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    Ralph A DeFronzo
    Division of Diabetes, University of Texas Health Science Center, San Antonio, TX, USA
    Diabetes Care 28:1092-100. 2005
    ..This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses...
  26. ncbi Managing people at high risk for diabetes
    William H Herman
    Ann Intern Med 144:66-7; author reply 67-8. 2006
  27. ncbi Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
    Sherwyn L Schwartz
    Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
    Clin Ther 30:858-67. 2008
    ..The aim of this study was to examine the glucose-lowering effect of exenatide over 24 hours in patients with type 2 diabetes with inadequate glycemic control using metformin, with or without a thiazolidinedione (TZD)...
  28. ncbi Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS)
    Marie Russell
    Phoenix Indian Medical Center, Phoenix, AZ, USA
    Am Heart J 152:867-75. 2006
    ....
  29. pmc Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program
    William H Hernan
    The Diabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, Rockville, Maryland 20852, USA
    Diabetes Care 26:36-47. 2003
    ..To describe the costs of the Diabetes Prevention Program (DPP) interventions to prevent or delay type 2 diabetes...
  30. ncbi Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy
    W Kline Bolton
    Department of Medicine, University of Virginia Health System, Charlottesville, Va 2908 0133, USA
    Am J Nephrol 24:32-40. 2004
    ..This study was undertaken to determine if pimagedine ameliorates nephropathy in type 1 (insulin-dependent) diabetes mellitus...
  31. ncbi Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study)
    Georgios I Papaioannou
    Cardiology Division, Henry Low Heart Center, Hartford Hospital, and University of Connecticut School of Medicine, Farmington, USA
    Am J Cardiol 94:294-9. 2004
    ..In addition, microalbuminuria is an independent predictor of endothelial dysfunction in asymptomatic patients with DM, especially in the absence of hormone replacement therapy...
  32. ncbi Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study
    Frans J Th Wackers
    Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Diabetes Care 27:1954-61. 2004
    ..To assess the prevalence and clinical predictors of silent myocardial ischemia in asymptomatic patients with type 2 diabetes and to test the effectiveness of current American Diabetes Association screening guidelines...
  33. pmc The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance
    William H Herman
    University of Michigan Health System, Ann Arbor, Michigan, USA
    Ann Intern Med 142:323-32. 2005
    ..The Diabetes Prevention Program (DPP) demonstrated that interventions can delay or prevent the development of type 2 diabetes...
  34. ncbi Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study
    Frans J Th Wackers
    Yale University School of Medicine, Section of Cardiovascular Medicine, 333 Cedar St Fitkin 3, New Haven, CT 06520, USA
    Diabetes Care 30:2892-8. 2007
    ..The purpose of this study was to assess whether the prevalence of inducible myocardial ischemia increases over time in patients with type 2 diabetes...
  35. ncbi Impact of computer-generated personalized goals on cholesterol lowering
    Claresa S Levetan
    Department of Internal Medicine, Lankenau Hospital, Wynnewood, PA 19096, USA
    Value Health 8:639-46. 2005
    ..This randomized, controlled trial was designed to evaluate the impact of a system that provides uniquely formatted laboratory results to patients with CVD on their changes in LDL-C levels...
  36. ncbi Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging
    Georgios I Papaioannou
    Henry Low Heart Center, Cardiology Division, Hartford Hospital, CT 06102, USA
    J Nucl Cardiol 13:362-8. 2006
    ..Myocardial perfusion imaging (MPI) is an effective method of detection of coronary artery disease (CAD); however, the relationship between endothelial function and MPI in asymptomatic patients with T2DM has not been examined...
  37. ncbi An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes
    Ronald T Ackermann
    Department of Medicine, Indiana University School of Medicine, 250 University Blvd, Suite 122, Indianapolis, IN 46202, USA
    Diabetes Care 29:1237-41. 2006
    ..We explored whether this intervention could be offered in a way that allows return on investment for private health insurers while remaining attractive for consumers, employers, and Medicare...
  38. pmc Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program
    Allan F Moore
    Center for Human Genetic Research, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Diabetes 57:2503-10. 2008
    ....